Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Clin Cancer Res. 2017 May 23;23(18):5648–5656. doi: 10.1158/1078-0432.CCR-17-0291

Figure 2. Overall survival (OS) and variant allele frequency (VAF) or Royal Marsden Hospital (RMH) score.

Figure 2

A. The median OS duration of the 38 patients with a mutant cell-free DNA (cfDNA) VAF of ≤6% (blue; 10.4 months; 95% confidence interval [CI], not estimated) was longer than that of the 17 patients with a mutated cfDNA VAF of >6% (red; 5.4 months; 95% CI, 3.0–7.8 months; P=0.018). B. The median OS duration of the 35 patients with an RMH score of 0 or 1 (blue; 12.6 months; 95% CI, not estimated) was significantly longer than that of the 20 patients with an RMH score of 2 or 3 (red; 3.8 months; 95% CI, 0.5–7.1 months; P=0.008). C. Among 35 patients with favorable RMH scores (0 or 1), the median OS duration of 25 patients with a mutated cfDNA VAF of ≤6% (blue; not reached) was longer than that of 10 patients with a mutated cfDNA VAF of >6% (red; 5.4 months; 95% CI, 3.1–7.7 months; P=0.001). D. Among 20 patients with unfavorable RMH scores (2 or 3), the median OS duration of 13 patients with a mutated cfDNA VAF of ≤6% (blue; 5.2 months; 95% CI, 0–10.8 months) was longer than that of 7 patients with a mutated cfDNA VAF of >6% (red; 3.6 months; 95% CI, 2.7–4.5 months) but this difference was not significant (P=0.73).